EA031798B1 - Применение ифенпродила для лечения диабета - Google Patents

Применение ифенпродила для лечения диабета Download PDF

Info

Publication number
EA031798B1
EA031798B1 EA201590849A EA201590849A EA031798B1 EA 031798 B1 EA031798 B1 EA 031798B1 EA 201590849 A EA201590849 A EA 201590849A EA 201590849 A EA201590849 A EA 201590849A EA 031798 B1 EA031798 B1 EA 031798B1
Authority
EA
Eurasian Patent Office
Prior art keywords
ifenprodil
glucose
metformin
diabetes
use according
Prior art date
Application number
EA201590849A
Other languages
English (en)
Russian (ru)
Other versions
EA201590849A1 (ru
Inventor
Даниель Коэн
Илья Чумаков
Сергей Набирошкин
Родольф Аж
Original Assignee
Фарнекст
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фарнекст filed Critical Фарнекст
Publication of EA201590849A1 publication Critical patent/EA201590849A1/ru
Publication of EA031798B1 publication Critical patent/EA031798B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA201590849A 2012-10-30 2013-10-30 Применение ифенпродила для лечения диабета EA031798B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261720156P 2012-10-30 2012-10-30
EP12306354.7A EP2727587A1 (en) 2012-10-30 2012-10-30 Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
PCT/EP2013/072728 WO2014068007A1 (en) 2012-10-30 2013-10-30 Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level

Publications (2)

Publication Number Publication Date
EA201590849A1 EA201590849A1 (ru) 2015-11-30
EA031798B1 true EA031798B1 (ru) 2019-02-28

Family

ID=47143792

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590849A EA031798B1 (ru) 2012-10-30 2013-10-30 Применение ифенпродила для лечения диабета

Country Status (17)

Country Link
US (2) US10092554B2 (enExample)
EP (3) EP2727587A1 (enExample)
JP (2) JP6387010B2 (enExample)
KR (1) KR20150081323A (enExample)
CN (2) CN104981240B (enExample)
AU (2) AU2013340826B2 (enExample)
BR (1) BR112015009702A2 (enExample)
CA (1) CA2888576C (enExample)
EA (1) EA031798B1 (enExample)
ES (2) ES2757846T3 (enExample)
HK (1) HK1214168A1 (enExample)
IL (1) IL238283A0 (enExample)
MX (1) MX2015005368A (enExample)
NZ (1) NZ707139A (enExample)
SG (2) SG11201503225UA (enExample)
WO (1) WO2014068007A1 (enExample)
ZA (1) ZA201503110B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3348261B1 (en) * 2012-03-01 2020-10-21 Pharnext New compositions comprising baclofen, acamprosate and riluzole
EP2890370B1 (en) 2012-08-31 2019-10-09 The Regents of the University of California Agents useful for treating obesity, diabetes and related disorders
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
CN105188692A (zh) * 2013-03-29 2015-12-23 国立大学法人熊本大学 2型糖尿病治疗剂
WO2014161836A1 (en) 2013-04-04 2014-10-09 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
EP3062782A1 (en) * 2013-10-30 2016-09-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
AU2014364999B2 (en) 2013-12-17 2019-12-12 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in feline animals
CN105960242A (zh) 2014-01-23 2016-09-21 勃林格殷格翰动物保健有限公司 犬科动物中代谢紊乱的治疗
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
KR20160111013A (ko) 2014-02-11 2016-09-23 파넥스트 신경질환의 치료를 위한 바클로펜, 아캄프로세이트 및 중쇄 트리-글리세리드의 조합
US10688116B2 (en) 2014-04-01 2020-06-23 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
KR102539788B1 (ko) * 2014-09-25 2023-06-07 베링거잉겔하임베트메디카게엠베하 말과 동물의 대사 장애를 예방하기 위한 sglt2 억제제와 도파민 작용제의 병용 치료
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
US9892234B2 (en) 2014-10-27 2018-02-13 Aseko, Inc. Subcutaneous outpatient management
CN104434952B (zh) * 2014-12-08 2017-10-24 成都恒瑞制药有限公司 一种治疗糖尿病的药物组合物及其制备方法
CN105055413A (zh) * 2015-07-23 2015-11-18 上海市第六人民医院 一种小檗碱和瑞格列奈的药物组合物
JP6858751B2 (ja) 2015-08-20 2021-04-14 アセコー インコーポレイテッド 糖尿病管理療法アドバイザ
PL3341024T3 (pl) 2015-08-27 2025-03-24 Boehringer Ingelheim Vetmedica Gmbh Ciekłe kompozycje farmaceutyczne zawierające inhibitory SGLT-2
US12359209B2 (en) 2018-04-17 2025-07-15 The Johns Hopkins Unversity Recombinant therapeutic interventions for cancer
US10918700B2 (en) * 2019-04-12 2021-02-16 Sdg, Inc. Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
WO2021158059A1 (ko) * 2020-02-07 2021-08-12 건국대학교 글로컬산학협력단 릴메니딘 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물
CA3194581A1 (en) * 2020-10-01 2022-04-07 Alok Singh Bcg based vaccine compositions and methods of use thereof
CN112294827B (zh) * 2020-11-12 2021-12-24 四川大学华西医院 5-胆甾烯 -3β-醇硫酸酯盐的用途
KR102543789B1 (ko) * 2021-03-08 2023-06-20 주식회사 온코크로스 토르세미드 및 크로몰린을 포함하는 대사질환 예방 또는 치료용 조성물
WO2022213353A1 (en) 2021-04-09 2022-10-13 Peking University Sirna, medical compositions, and methods for treating diabetes using the same
WO2022225984A1 (en) * 2021-04-19 2022-10-27 Spruce Health Sciences Inc. Nutritional supplement for regulating blood sugar
KR20250038064A (ko) 2023-09-11 2025-03-19 김강숙 산양삼을 함유하는 김부각의 제조 방법 및 그 방법에 의해 제조된 김부각

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162754A1 (en) * 2001-12-17 2003-08-28 Tufts University Use of GABA and GABAB agonists
WO2004011003A1 (en) * 2002-07-25 2004-02-05 Pharmacia Italia S.P.A. Nicergoline, mmdl and mdl for the treatment of neurodegenerative disorders of the retina and optic nerve
US20050025714A1 (en) * 1997-10-01 2005-02-03 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
GB2432526A (en) * 2005-11-24 2007-05-30 Arakis Ltd Use of ifenprodil for the treatment of ophthalmic diseases
EP1884513A1 (en) * 2005-05-23 2008-02-06 Japan Tobacco, Inc. Pyrazole compound and therapeutic agent for diabetes comprising the same
US20080213362A1 (en) * 2007-02-02 2008-09-04 Lawrence Solomon Compositions and methods using torsemide
WO2008141189A1 (en) * 2007-05-09 2008-11-20 Elixir Pharmaceuticals, Inc. Ghrelin modulating compounds and combinations thereof
WO2014013025A1 (en) * 2012-07-18 2014-01-23 Pharnext Baclofen and acamprosate based therapy of macular degeneration disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2314719A1 (fr) * 1975-04-11 1977-01-14 Roussel Uclaf Nouveau medicament notamment diuretique
IT1157365B (it) * 1977-10-24 1987-02-11 Sandoz Ag Medicamenti per trattare l'obesita' o ridurre il peso del corpo
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
JPH059114A (ja) * 1990-08-29 1993-01-19 Takeda Chem Ind Ltd 糖尿病性合併症の予防・治療剤
JP4821037B2 (ja) 2000-08-25 2011-11-24 富士通株式会社 ラマン増幅を用いた光増幅器およびラマン励起光源
US20030069221A1 (en) * 2001-01-26 2003-04-10 Schering Corporation Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
BR0307336A (pt) * 2002-01-30 2004-12-07 Pharmacia Corp Terapia combinada do antagonista do receptor da aldosterona e do agente modulador alfa-adrenérgico para prevenção ou tratamento de condições patogênicas
EP1725226A2 (en) * 2004-03-17 2006-11-29 Sosei R&D Ltd. The treatment of inflammatory disorders and pain using beta-aminoalcohols
KR20080009203A (ko) * 2005-05-10 2008-01-25 라보라뚜와르 푸르니에 에스.아. 리버 엑스 리셉터 어고니스트의 신규한 용도
EP1991211A1 (en) * 2006-02-28 2008-11-19 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
EP1829534A1 (en) * 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
WO2008112167A1 (en) * 2007-03-09 2008-09-18 Indigene Pharmaceuticals Inc. Combination of metformin r-(+) lipoate and antihypertensive agents for the treatment of diabetic hyperglycemia and diabetic complications
JP2010536880A (ja) * 2007-08-22 2010-12-02 ギリード・コロラド・インコーポレーテッド 糖尿病の合併症のための療法
AP2011005794A0 (en) * 2009-02-13 2011-08-31 Boehringer Ingelheim Int Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a furtherantidiabetic agent and uses thereof.
UA115968C2 (uk) * 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
AU2012312266A1 (en) * 2011-09-21 2013-05-02 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050025714A1 (en) * 1997-10-01 2005-02-03 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20030162754A1 (en) * 2001-12-17 2003-08-28 Tufts University Use of GABA and GABAB agonists
WO2004011003A1 (en) * 2002-07-25 2004-02-05 Pharmacia Italia S.P.A. Nicergoline, mmdl and mdl for the treatment of neurodegenerative disorders of the retina and optic nerve
EP1884513A1 (en) * 2005-05-23 2008-02-06 Japan Tobacco, Inc. Pyrazole compound and therapeutic agent for diabetes comprising the same
GB2432526A (en) * 2005-11-24 2007-05-30 Arakis Ltd Use of ifenprodil for the treatment of ophthalmic diseases
US20080213362A1 (en) * 2007-02-02 2008-09-04 Lawrence Solomon Compositions and methods using torsemide
WO2008141189A1 (en) * 2007-05-09 2008-11-20 Elixir Pharmaceuticals, Inc. Ghrelin modulating compounds and combinations thereof
WO2014013025A1 (en) * 2012-07-18 2014-01-23 Pharnext Baclofen and acamprosate based therapy of macular degeneration disorders

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
"Metformin/Repaglinide (PrandiMet) for type 2 diabetes.", THE MEDICAL LETTER ON DRUGS AND THERAPEUTICS, USA, vol. 51, no. 1313, 1 June 2009 (2009-06-01), USA, pages 41 - 43, XP009177448, ISSN: 1523-2859 *
ANGHINAH R; OLIVEIRA A S B; GABBAL A A: "Effect of baclofen on pain in diabetic neuropathy [4]", MUSCLE AND NERVEMUSCLE, vol. 17, no. 8, 1 August 1994 (1994-08-01), pages 958 - 959, XP009177368, ISSN: 0148-639X *
BEALES P E, ET AL.: "BACLOFEN, A GAMMA-AMINOBUTYRIC ACID-B RECEPTOR AGONIST, DELAYS DIABETES ONSETIN THE NON-OBESE DIABETIC MOUSE", ACTA DIABETOLOGICA., SPRINGER INTERNATIONAL, BERLIN., DE, vol. 32, no. 01, 1 March 1995 (1995-03-01), DE, pages 53 - 56, XP001095343, ISSN: 0940-5429, DOI: 10.1007/BF00581047 *
CRINQUETTE J-F; COLOMBEL J-F; MAY J P; CHANTRE M; CLAERBOUT J-F; BONVARLET F; BONVARLET P: "A DIFFUSE FORM OF DUCTAL ECTASIA OF THE PANCREAS", GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, PARIS, FR, vol. 12, no. 11, 1 January 1988 (1988-01-01), FR, pages 866 - 867, XP009175923, ISSN: 0399-8320 *
DUNN C. J., PETERS D. H.: "A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN NON-INSULIN-DEPENDENT DIABETES MELLITUS.", DRUGS, ADIS INTERNATIONAL LTD., NZ, vol. 49., no. 05., 1 May 1995 (1995-05-01), NZ, pages 721 - 749., XP000921043, ISSN: 0012-6667, DOI: 10.2165/00003495-199549050-00007 *
FREYRIA J: "Clinical trial with an antiischemic drug in atherosclerotic and diabetic arteriopathies = Essai de la thérapeutique anti-ischémique dans le traitement des artériopathies de surchage", GAZETTE MEDICALE DE FRANCE., PARIS., FR, vol. 82, no. 16, 1 January 1975 (1975-01-01), FR, pages 1989 - 1990, 1993-1996, XP009175880, ISSN: 0016-5557 *
GOMEZ R, ET AL.: "GABA AGONISTS DIFFERENTIALLY MODIFY BLOOD GLUCOSE LEVELS OF DIABETIC RATS", JAPANESE JOURNAL OF PHARMACOLOGY., THE JAPANESE PHARMACOLOGICAL SOCIETY, KYOTO, JP, vol. 80, no. 04, 1 August 1999 (1999-08-01), KYOTO, JP, pages 327 - 331, XP001095576, ISSN: 0021-5198, DOI: 10.1254/jjp.80.327 *
HOLLENBERG N K; MICKIEWICZ C: "HYPERKALEMIA IN DIABETES MELLITUS EFFECT OF A TRIAMTERENE HYDROCHLOROTHIAZIDE COMBINATION", ARCHIVES OF INTERNAL MEDICINE., AMERICAN MEDICAL ASSOCIATION, US, vol. 149, no. 6, 1 June 1989 (1989-06-01), US, pages 1327 - 1330, XP009177371, ISSN: 0003-9926, DOI: 10.1001/archinte.149.6.1327 *
LANGEVIN J. ET AL.: "Etude du tartrate d' ifenprodil dans le traitement des accidents vasculaires c�r�braux aigus", OUEST MEDICAL., EXPANSION SCIENTIFIQUE FRANCAISE, PARIS., FR, vol. 29., 20 May 1976 (1976-05-20), FR, pages 853/854., XP002088157, ISSN: 0048-2366 *
LEHNERT H; SCHMITZ H; BEYER J; WILMBUSSE H; PIESCHE L: "Controlled clinical trial investigating the influence of torasemide and furosemide on carbohydrate metabolism in patients with cardiac failure and concomitant type II diabetes", INTERNATIONAL CONGRESS SERIES., EXCERPTA MEDICA, AMSTERDAM., NL, 1 January 1993 (1993-01-01), NL, pages 271 - 274, XP009177369, ISSN: 0531-5131 *
SABBAH A: "PHARMACOLOGICAL BIOLOGICAL AND CLINICAL EFFECTS OF A NEW ANTI ASTHMATIC FENSPIRIDE", PHARMACOLOGIST, vol. 11, no. 2, 1 January 1969 (1969-01-01), pages 266, XP009177442, ISSN: 0031-7004 *
SALEM H; SHEMANO I; BEILER J M; ORZECHOWSKI R; HITCHENS J T; CLEMENTE E: "FENSPIRIDE A NONSYMPATHOMIMETIC BRONCHO DILATOR WITH ANTI ALLERGIC ACTIVITY", ARCHIVES INTERNATIONALES DE PHARMACODYNAMIE ET DE THERAPIE, vol. 193, no. 1, 1 January 1971 (1971-01-01), pages 111 - 123, XP009177441, ISSN: 0003-9780 *
SEITZ RUEDIGER J; BLANK BETTINA; KIWIT JUERGEN C W; BENECKE REINER: "Stiff-person syndrome with anti-glutamic acid decarboxylase autoantibodies: Complete remission of symptoms after intrathecal baclofen administration", JOURNAL OF NEUROLOGY - ZEITSCHRIFT FUER NEUROLOGIE, SPRINGER VERLAG, BERLIN., DE, vol. 242, no. 10, 1 October 1995 (1995-10-01), DE, pages 618 - 622, XP009177376, ISSN: 0340-5354, DOI: 10.1007/BF00866910 *
WALKER B R; CAPUZZI D M; ALEXANDER F; FAMILIAR R G; HOPPE R C: "HYPERKALEMIA AFTER TRIAMTERENE IN DIABETIC PATIENTS", CLINICAL PHARMACOLOGY AND THERAPEUTICS, NATURE PUBLISHING GROUP, US, vol. 13, no. 5, part 1, 1 January 1972 (1972-01-01), US, pages 643 - 651, XP009168825, ISSN: 0009-9236, DOI: 10.1002/cpt1972135part1643 *
WEICHENHAIN B, KOOTEN VAN H-J, STANDL E: "HYPERTENSION AND INSULIN RESISTANCE GLYCAEMIA AND INSULINAEMIA IN OVERWEIGHT HYPERTENSIVE PATIENTS", DRUGS, ADIS INTERNATIONAL LTD., NZ, vol. 46, no. SUPPL. 02, 1 January 1993 (1993-01-01), NZ, pages 183 - 188, XP001097733, ISSN: 0012-6667, DOI: 10.2165/00003495-199300462-00028 *
YAMASHITA S; NUMOTO T; TAKENAGA K; SHIMIZU K; YAMAURA T; UMEHARA N; OBA M; AOYAMA M; NOGUCHI K; ET AL: "GENERAL PHARMACOLOGICAL ACTIVITIES OF N-2 METHYL-3-CHLOROPHENYL ANTHRANILIC-ACID GEA-6414", IGAKKAI ZASSHI -JOURNAL OF MEDICAL SOCIETY OF TOHO UNIVERSITY, TOHO DAIGAKU IGAKUBU IGAKKAI, TOKYO, JP, vol. 28, no. 4, 1 January 1981 (1981-01-01), JP, pages 685 - 697, XP009177377, ISSN: 0040-8670 *
Yamashita Y.: "EFFECT OF 2-(4-BENZYL-PIPERIDIN)-1-(4-HYDROXYPHENYL)-1-PROPANOL ON BLOOD GLUCOSE CONCENTRATION", 15 December 1979 (1979-12-15), XP055099599, Retrieved from the Internet: URL:http://ac.els-cdn.com/0006295279903915/1-s2.0-0006295279903915-main.pdf?_tid=bac 12656-8a5b-11e3-a971-00000aab0f6b&acdnat=1391161413_84a229c13ef1d04933704cceb9fledb9 [retrieved on 2014-01-31], the whole document, in particular, page 3503, column 1, paragraph 2 *

Also Published As

Publication number Publication date
US20150231123A1 (en) 2015-08-20
KR20150081323A (ko) 2015-07-13
EP2914252B1 (en) 2019-09-04
JP6387010B2 (ja) 2018-09-05
CA2888576A1 (en) 2014-05-08
EA201590849A1 (ru) 2015-11-30
SG11201503225UA (en) 2015-05-28
EP3482753B1 (en) 2021-01-27
WO2014068007A1 (en) 2014-05-08
EP2727587A1 (en) 2014-05-07
CN104981240B (zh) 2019-03-15
BR112015009702A2 (pt) 2019-12-17
AU2013340826A1 (en) 2015-05-07
SG10201801695XA (en) 2018-04-27
US10596160B2 (en) 2020-03-24
CN104981240A (zh) 2015-10-14
ES2870028T3 (es) 2021-10-26
ES2757846T3 (es) 2020-04-30
HK1214168A1 (zh) 2016-07-22
AU2018253580B2 (en) 2020-04-30
MX2015005368A (es) 2015-07-21
AU2013340826B2 (en) 2018-07-26
EP3482753A1 (en) 2019-05-15
NZ707139A (en) 2019-01-25
EP2914252A1 (en) 2015-09-09
JP2018188473A (ja) 2018-11-29
JP2016501841A (ja) 2016-01-21
CN110141663A (zh) 2019-08-20
US20190008841A1 (en) 2019-01-10
AU2018253580A1 (en) 2018-11-22
CA2888576C (en) 2021-02-16
IL238283A0 (en) 2015-06-30
ZA201503110B (en) 2016-08-31
US10092554B2 (en) 2018-10-09

Similar Documents

Publication Publication Date Title
AU2018253580B2 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
US20200222409A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
US20100093861A1 (en) Treatment of insulin resistance or diseases associated with insulin resistance
JP2007514771A (ja) 糖尿病を治療するための組成物および方法
CN101541323A (zh) 吲唑甲氧基烷酸用于降低甘油三酯、胆固醇和葡萄糖水平的用途
TW201029995A (en) Use of eltoprazine for the treatment of L-DOPA-induced dyskinesia
RU2653478C2 (ru) Способ улучшения функции печени
Mousa et al. Literature review of oral treatment of type 2 diabetes mellitus
WO2022061962A1 (zh) 一种l型氨基酸转运蛋白抑制剂或拮抗剂有效干预糖尿病的方法
WO2024079677A1 (en) Novel therapeutic molecule
US20150025027A1 (en) Combination of a Monosubstituted Sulfamate Derivate of the Natural Monosaccharide d-Fructose (Topiramate) with an Anti-Depressant from the Phenyl Ketone Class (Bupropion) for Treating Obesity and Plurimetabolic Syndromes
HK40071125A (en) Composition used for combating metabolic diseases and uses of composition
HK1162961A (en) Treatment of insulin resistance or diseases associated with insulin resistance using steviol or isosteviol
BR102014006729A2 (pt) métodos terapêuticos e composições para tratamento de diabetes utilizando compostos de diterpenoides

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU